Amphastar Pharmaceuticals, Inc.
AMPH
$27.23
-$0.36-1.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 191.84M | 174.41M | 170.53M | 186.98M | 188.82M |
| Total Other Revenue | -- | -- | -- | -455.00K | 2.40M |
| Total Revenue | 191.84M | 174.41M | 170.53M | 186.52M | 191.21M |
| Cost of Revenue | 93.19M | 87.92M | 85.28M | 99.88M | 89.27M |
| Gross Profit | 98.65M | 86.49M | 85.25M | 86.65M | 101.94M |
| SG&A Expenses | 50.97M | 24.23M | 27.86M | 23.36M | 23.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 166.52M | 132.23M | 133.24M | 141.38M | 134.17M |
| Operating Income | 25.32M | 42.18M | 37.29M | 45.14M | 57.05M |
| Income Before Tax | 21.51M | 39.34M | 30.86M | 43.96M | 47.68M |
| Income Tax Expenses | 4.16M | 8.31M | 5.58M | 6.00M | 7.25M |
| Earnings from Continuing Operations | 17.35M | 31.03M | 25.29M | 37.96M | 40.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.35M | 31.03M | 25.29M | 37.96M | 40.43M |
| EBIT | 25.32M | 42.18M | 37.29M | 45.14M | 57.05M |
| EBITDA | 39.45M | 56.80M | 50.90M | 58.58M | 70.45M |
| EPS Basic | 0.37 | 0.66 | 0.53 | 0.79 | 0.83 |
| Normalized Basic EPS | 0.29 | 0.52 | 0.40 | 0.57 | 0.61 |
| EPS Diluted | 0.37 | 0.64 | 0.51 | 0.74 | 0.78 |
| Normalized Diluted EPS | 0.28 | 0.51 | 0.39 | 0.54 | 0.57 |
| Average Basic Shares Outstanding | 46.47M | 46.95M | 47.64M | 47.98M | 48.62M |
| Average Diluted Shares Outstanding | 47.68M | 48.13M | 49.89M | 51.31M | 51.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |